Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
12 mars 2018 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
02 oct. 2017 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting
28 sept. 2017 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its...
Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
14 sept. 2017 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO,...
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
07 sept. 2017 07h50 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
28 juil. 2017 07h30 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
27 juil. 2017 16h11 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
03 mai 2017 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
11 avr. 2017 07h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
16 mars 2017 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical...